STAT+: Lawmakers want FTC to probe big PBMs over private-label biosimilar deals
STAT
OCTOBER 2, 2024
In reality, the arrangements actually resemble private-label distribution, but the lawmakers worry these agreements could cause consumers to pay higher prices. These new business units have since used these deals as springboards to market the medications to health plans.
Let's personalize your content